---
title: "AHWB released its 2024 annual performance, with a net profit attributable to the parent company of 85.5307 million yuan, a decrease of 20.87%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236785262.md"
description: "AHWB released its 2024 annual report, with operating revenue of 379 million yuan, a year-on-year increase of 10.91%. The net profit attributable to shareholders was 85.5307 million yuan, a year-on-year decrease of 20.87%; the net profit after deducting non-recurring gains and losses was 55.7878 million yuan, a year-on-year decrease of 42.90%. The basic earnings per share were 1.28 yuan"
datetime: "2025-04-21T11:56:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236785262.md)
  - [en](https://longbridge.com/en/news/236785262.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236785262.md)
---

# AHWB released its 2024 annual performance, with a net profit attributable to the parent company of 85.5307 million yuan, a decrease of 20.87%

According to the Zhitong Finance APP, AHWB (301520.SZ) released its annual report for 2024, with operating revenue of 379 million yuan, a year-on-year increase of 10.91%. The net profit attributable to shareholders of the listed company was 85.5307 million yuan, a year-on-year decrease of 20.87%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 55.7878 million yuan, a year-on-year decrease of 42.90%. The basic earnings per share were 1.28 yuan

### Related Stocks

- [301520.CN](https://longbridge.com/en/quote/301520.CN.md)

## Related News & Research

- [FREDUN: Strong revenue and profit growth with robust compliance in the pharmaceutical segment](https://longbridge.com/en/news/294919739.md)
- [Biovica says Clinical Cancer Research study links low DiviTum TKa levels to early benefit in advanced breast cancer trial](https://longbridge.com/en/news/294781247.md)
- [Aravax wins FDA Fast Track status for PVX108 peanut allergy therapy](https://longbridge.com/en/news/294784983.md)
- [India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body says](https://longbridge.com/en/news/294772343.md)
- [10:30 ETResearch Use Recombinant Protein Market worth USD 1.55 billion by 2031 - Exclusive Report by MarketsandMarkets™](https://longbridge.com/en/news/294840536.md)